SURVYR

MIST

Milestone Pharmaceuticals Inc.
$0.64
−$0.00 (0.56%)Oct 26 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-67%-35%-3%+28%+60%Oct 2025Oct 2026Apr 202652w high $3.0652w low $0.63
MISTSPY
Wall St. Highest PT $8.00 (+1141.5%) Wall St. Avg PT $5.57 (+764.6%)
$1$3$6$8$11POC $1Hi $8Avg $6
Underwater Drawdown %Max DD -78.2%Current -78.2%
0.0%-78.2%
Relative Strength vs SPY-79.2% vs SPYUnderperforming
+91%0%-91%
1W
−$0.06 (7.94%)
1M
−$0.14 (18.22%)
3M
−$0.49 (42.97%)
6M
−$1.22 (65.35%)
YTD
−$1.38 (68.10%)
1Y
−$1.24 (65.72%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
7 analysts · mean score 1.43
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$0.64
Average target$5.57
+$4.93 (+764.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$1.00
Median$5.57
High$8.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-09-03 · HC Wainwright & Co. reiterated Buy on MIST
Initiated
2026-08-20 · Cantor Fitzgerald started covering MIST at Overweight
Reiterated
2026-05-14 · Wells Fargo reiterated Overweight on MIST
Reiterated
2026-01-06 · HC Wainwright & Co. reiterated Buy on MIST
Reiterated
2025-12-16 · Wells Fargo reiterated Overweight on MIST
Upgrade
2025-12-15 · TD Cowen upgraded MIST from Hold to Buy
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$80.7M
P/E (next 12 months, estimated)-0.8
52-week range$0.63 – $3.06
Dividend yieldNo dividend
Analyst consensusStrong Buy (7)
Average analyst price target$5.57 (+765%)

What they do

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for MIST yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

MIST earningsNext report in 15 days
Next report
Thu Nov 12, 2026Before the open
EPS consensus-$0.21 range -$0.23–-$0.20
Revenue consensus$1.0M 7 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026-$0.21est -$0.19−9.1%Below estimates
May 13, 2026-$0.20est $0.19−206.7%Below estimates
Mar 20, 2026-$0.15est -$0.18+15.1%Above estimates
Nov 12, 2025-$0.12est -$0.17+28.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 00:04:36 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.310.19
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$559.0K–
2026-03-31$238.0K–
2025-12-31$1.5M–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst Expectations
Simply Wall St. · Oct 23
AO+ Probiotic Topical Mist Returns -- Now in Two New Higher-Concentration Formulas
PR Newswire · Oct 20
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
GlobeNewswire · Oct 19
United Therapeutics Gets FDA Clearance to Start Phase 2 Trial of Treprostinil Soft Mist Inhaler
MT Newswires · Oct 19
Milestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial Fibrillation
MT Newswires · Oct 09
Rating changes
Reiterated
2026-09-03 · HC Wainwright & Co. reiterated Buy on MIST
Initiated
2026-08-20 · Cantor Fitzgerald started covering MIST at Overweight
Reiterated
2026-05-14 · Wells Fargo reiterated Overweight on MIST
Reiterated
2026-01-06 · HC Wainwright & Co. reiterated Buy on MIST
Reiterated
2025-12-16 · Wells Fargo reiterated Overweight on MIST
Upgrade
2025-12-15 · TD Cowen upgraded MIST from Hold to Buy

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-24 00:04:36 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026